Author

L. Ireland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Mielgo· 3 shared A. Santos· 2 shared M. Schmid· 2 shared C. Figueiredo· 1 shared C. R. Figueiredo· 1 shared F. Campbell· 1 shared L. Ellies· 1 shared L. Polonelli· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Mielgo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Blockade of stromal Gas6 alters cancer cell plasticity, activates NK cells and inhibits pancreatic cancer metastasis.

A. Mielgo, L. Ireland, T. Luckett, M. C. Schmid

This study shows that blocking Gas6 in pancreatic cancer reduces metastasis by reversing EMT and activating NK cells, suggesting Gas6 as a therapeutic target.

bioRxiv · Aug 12, 2019Cancer Biology

Interfering with MIF-CD74 signalling on macrophages and dendritic cells with a peptide-based approach restores the immune response against metastatic melanoma.

C. R. Figueiredo, R. A. Azevedo, S. Mousdell, P. T. Resende-Lara, L. Ireland, A. Santos, N. Girola, R. L. O. R. Cunha, M. Schmid, L. Polonelli, L. R. Travassos, A. Mielgo

This study shows that a peptide-based therapy targeting the MIF-CD74 pathway in macrophages and dendritic cells can restore anti-tumour immunity in metastatic melanoma.

bioRxiv · Jan 16, 2018Cancer Biology

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.

L. Ireland, A. Santos, F. Campbell, C. Figueiredo, L. Ellies, U. Weyer-Czernilofsky, T. Bogenrieder, M. Schmid, A. Mielgo

This study shows that blocking insulin-like growth factors enhances paclitaxel's effectiveness against metastatic breast cancer by reducing tumor growth and lung metastasis in pre-clinical models.

bioRxiv · Jul 23, 2017Cancer Biology